Customer No. 28880

Confirmation No. 5971

PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pacework Reduction Act of 1995, no cersons are regulared to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/644,516 TRANSMITTAL Filing Date August 20, 2003 **FORM** First Named Inventor Stephen K. MacLeod Art Unit 3761 Examiner Name Leslie R. Deak (to be used for all correspondence after initial filling Attorney Docket Number PC27664A Total Number of Pages In This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittel Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please identify Terminal Disclaimer Extension of Time Request below); Express Abandonment Request Request for Refund CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Authorization to charge the fee and any additional fees as necessary or credit any Reply to Missing Parts/ overpayment to deposit account 23-0455 is hereby given. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Karen B. King Reg. No. January 20, 2006 41.898 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPRO or deposited with the United States Postal Service with sufficient postage as first class mail in an epvelope addressed to: Complissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Wanda C. Bland Typed or printed name January 20, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No.

571-273-8300

PATENT PFIZER ANN ARBOR MI

CHAMBER VIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 2 0 2006

APPLICANT: Stephen K. MacLeod) DOCKET NO.: PC27664A)
SERIAL NO.: 10/644,516) GROUP ART UNIT: 3761
)
FILED: August 20, 2003) EXAMINER: Leslie R. Deak
TITLE: INJECTABLE PHARMACEUTICAL SUSPENSION IN A TWO-

CERTIFICATE OF TRANSMISSION

I, Wanda Bland, hereby certify that this correspondence and any accompanying documents recited herein, below, are being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571)273-8300 on hounted office

Signed:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND REPLY, UNDER 37 CFR 1.111

Dear Honorable Commissioner:

In response to an Office Action mailed October 20, 2005 Applicant respectfully submits this Amendment and Reply, under 37 CFR §1.111. Applicant respectfully requests reconsideration of the claims in view of the following.

Amendments to the specification begin on page 2.

Claim amendments begin on page 3.

Remarks begin on page 8.